医疗卫生机构抗肿瘤类药品中标价格差异情况分析

Analysis of Bid Price Differences of Anti-tumor Drugs in Medical Institutions

目的:了解医疗卫生机构采购金额较大的抗肿瘤类药品中标价格情况,为减轻肿瘤患者的经济负担提供参考和建议。方法:收集和整理2012年部分省(区、市)医疗卫生机构药品采购数据,对其中抗肿瘤类药品中标价格进行统计和分析。结果:大部分药品的省间中标价格差异在1倍以内,其中细胞毒类非国家医保目录范围内药品平均中标价格是国家医保目录范围内药品平均中标价格的3.89倍,中成药类国家医保目录范围内药品平均中标价格是非国家医保目录范围内药品平均中标价格的0.61倍;与其他类别药品相比,抗肿瘤类药品中标价格相对较高。结论:建议鼓励加强对独家药品的仿制研发,在药物经济学分析的基础上确定医保支付价,提高相关药品的报销比例,以缓解患者负担。

OBJECTIVE： To investigate the bid price of anti-tumor drugs which is large in amount and purchased by medical in- stitutions, and to provide reference and suggestions for reducing economical burden of patients. METHODS： The drug procurement price data were collected from some provincial （regional or municipal） medical institutions in 2012, and the bid price of anti-tumor drugs was analyzed statistically. RESULTS： There was 1 times price difference of most drugs among provinces. The average bid price of cytotoxic drug out of directory of national health insurance was 3.89 times of that of the drugs in directory of national health insurance. The average bid price of Chinese patent medicine in the directory of national health insurance was 0.61 times of that out of the directory of national health insurance. Compared with other types, the bid price of antitumor drugs were relatively high. CONCLUSIONS ： It is suggested to strengthen the research and development of exclusive drugs, and determine Medicare pay- ment price on the basis of pharmacoeconomics, and improve proportion of reimbursement and relieve the burden of patients.